Showing results (1-10 of 67) with videos related to
Sort By:
Pageof 7
Current Opinion in Supportive and Palliative Care|August 8, 2008
RANKL signaling in bone physiology and cancerWilliam C DougallClinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 28, 2011
Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasisWilliam C DougallCancer Metastasis Reviews|December 21, 2006
The RANK/RANKL/OPG triad in cancer-induced bone diseasesWilliam C Dougall, Michelle ChaissonCancer Treatment Reviews|October 30, 2007
RANK ligand as a therapeutic target for bone metastases and multiple myelomaG David Roodman, William C DougallBonekey Reports|May 6, 2014
Targeting RANKL in metastasisWilliam C Dougall, Ingunn Holen, Eva González SuárezClinical & Translational Immunology|October 2, 2019
Dual targeting of RANKL and PD-1 with a bispecific antibody improves anti-tumor immunityWilliam C Dougall, Amelia Roman Aguilera, Mark J SmythClinical & Experimental Metastasis|August 17, 2006
Effects of the RANKL inhibitor, osteoprotegerin, on the pain and histopathology of bone cancer in ratsMartine P Roudier, Steven D Bain, William C DougallImmunological Reviews|March 5, 2017
TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapyWilliam C Dougall, Sema Kurtulus, Mark J Smyth, et al.Breast Cancer Research and Treatment|August 29, 2012
RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis modelJude Canon, Rebecca Bryant, Martine Roudier, et al.Nature Reviews. Clinical Oncology|September 21, 2018
Roles of the RANKL-RANK axis in antitumour immunity - implications for therapyElizabeth Ahern, Mark J Smyth, William C Dougall, et al.Pageof 7